Anifrolumab for Treatment of Refractory Cutaneous Lupus Erythematosus
Clin Exp Dermatol. 2022. Epub ahead of print doi:10.1111/ced.15335
Following the FDA approval of anifrolumab for the treatment of patients with moderate-to-severe CLE, Blum, et al. present a case series of patients demonstrating significant improvement in disease appearance, cutaneous involvement, and symptomology after treatment with two months of anifrolumab infusions.